Atara Biotherapeutics, Inc. (0HIY.L)
USD 5.56
(2.59%)
USD 5.56
(2.59%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -313 Thousand USD | -100.64% |
| 2022 | 49 Million USD | 446.93% |
| 2021 | 8.96 Million USD | 190.81% |
| 2020 | -9.86 Million USD | -21.74% |
| 2019 | -8.1 Million USD | -114.36% |
| 2018 | -3.78 Million USD | -295.5% |
| 2017 | -956 Thousand USD | -149.61% |
| 2016 | -383 Thousand USD | -697.92% |
| 2015 | -48 Thousand USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 24.01 Million USD | -5.36% |
| 2024 Q1 | 25.37 Million USD | 2223.44% |
| 2023 Q1 | 1.01 Million USD | 126.26% |
| 2023 FY | -313 Thousand USD | -100.64% |
| 2023 Q4 | 1.09 Million USD | 328.93% |
| 2023 Q3 | -477 Thousand USD | 75.39% |
| 2023 Q2 | -1.93 Million USD | -291.88% |
| 2022 Q4 | -3.84 Million USD | -1309.43% |
| 2022 Q1 | 5.08 Million USD | 16.61% |
| 2022 Q2 | -13.31 Million USD | -361.72% |
| 2022 FY | 49 Million USD | 446.93% |
| 2022 Q3 | 318 Thousand USD | 102.39% |
| 2021 Q3 | -64.96 Million USD | -0.55% |
| 2021 Q4 | 4.36 Million USD | 106.72% |
| 2021 Q1 | 957 Thousand USD | -99.47% |
| 2021 FY | 8.96 Million USD | 190.81% |
| 2021 Q2 | -64.6 Million USD | -6850.78% |
| 2020 Q4 | 179.09 Million USD | 399.11% |
| 2020 Q1 | -57.65 Million USD | 0.0% |
| 2020 Q2 | -61.56 Million USD | -6.77% |
| 2020 Q3 | -59.87 Million USD | 2.73% |
| 2020 FY | -9.86 Million USD | -21.74% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | -8.1 Million USD | -114.36% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | -3.78 Million USD | -295.5% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | -956 Thousand USD | -149.61% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | -383 Thousand USD | -697.92% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 FY | -48 Thousand USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 100.002% |
| Dynavax Technologies Corporation | 182.11 Million USD | 100.172% |
| Illumina, Inc. | 2.74 Billion USD | 100.011% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 100.006% |
| Biogen Inc. | 7.3 Billion USD | 100.004% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 96.728% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 100.014% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 100.029% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 100.06% |
| Waters Corporation | 1.76 Billion USD | 100.018% |
| Perrigo Company plc | 1.68 Billion USD | 100.019% |
| uniQure N.V. | 2.21 Million USD | 114.131% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 101.807% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 100.086% |
| bluebird bio, Inc. | -4.03 Million USD | 92.233% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 102.116% |
| Imunon, Inc. | -720 Thousand USD | 56.528% |
| Myriad Genetics, Inc. | 476.4 Million USD | 100.066% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 100.017% |
| Nektar Therapeutics | 53.47 Million USD | 100.585% |
| Editas Medicine, Inc. | -99.52 Million USD | 99.686% |
| Verastem, Inc. | -62 Thousand USD | -404.839% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 100.001% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 98.996% |
| Heron Therapeutics, Inc. | 10.04 Million USD | 103.117% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 98.411% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 100.016% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 99.309% |
| Evolus, Inc. | 140.52 Million USD | 100.223% |
| Adicet Bio, Inc. | -6.09 Million USD | 94.867% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 99.633% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 100.003% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 100.428% |
| FibroGen, Inc. | 128.9 Million USD | 100.243% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 100.009% |
| OPKO Health, Inc. | 318.12 Million USD | 100.098% |
| Homology Medicines, Inc. | -7.22 Million USD | 95.67% |
| Geron Corporation | -123.5 Million USD | 99.747% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 100.021% |
| Exelixis, Inc. | 1.75 Billion USD | 100.018% |
| Viking Therapeutics, Inc. | -292 Thousand USD | -7.192% |
| Anavex Life Sciences Corp. | - USD | Infinity% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 99.922% |
| Zoetis Inc. | 5.83 Billion USD | 100.005% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 100.128% |
| Abeona Therapeutics Inc. | 302 Thousand USD | 203.642% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 100.004% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | -3.3% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 100.04% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 100.066% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 100.049% |
| Blueprint Medicines Corporation | 236.58 Million USD | 100.132% |
| Insmed Incorporated | 239.63 Million USD | 100.131% |
| TG Therapeutics, Inc. | 219.1 Million USD | 100.143% |
| Incyte Corporation | 3.44 Billion USD | 100.009% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 100.091% |